BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36967267)

  • 1. SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS).
    Saunders MP; Iype R; Kelly C; Crosby J; Kerr R; Harkin A; Allan K; McQueen J; Pearson SR; Cassidy J; Medley LC; Raouf S; Harrison M; Brewster A; Rees C; Ellis R; Thomas AL; Churn M; Iveson T; Maka N
    Clin Colorectal Cancer; 2023 Jun; 22(2):231-237. PubMed ID: 36967267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study.
    Atci MM; Akagunduz B; Demir M; Arikan R; Ay S; Ozer M; Ayhan M; Cil I; Demir N; Ozyurt N; Karakaya G; Cevik GT; Onder AH; Selvi O; Sakin A
    J Chemother; 2023 Feb; 35(1):19-28. PubMed ID: 35174772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance].
    Saberzadeh-Ardestani B; Foster NR; Lee HE; Shi Q; Alberts SR; Smyrk TC; Sinicrope FA
    Ann Oncol; 2022 Nov; 33(11):1159-1167. PubMed ID: 35963480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Impact of Primary Tumor Sidedness in Stage III Colorectal Cancer: Real-World Evidence from a Brazilian Cohort.
    Protásio BM; de Castria TB; Natalino R; Mangone FR; Saragiotto DF; Sabbaga J; Hoff PM; Chammas R
    Clin Colorectal Cancer; 2024 Mar; 23(1):73-84. PubMed ID: 38151358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
    Iveson T; Boyd KA; Kerr RS; Robles-Zurita J; Saunders MP; Briggs AH; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Pearson S; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan H; Paul J
    Health Technol Assess; 2019 Dec; 23(64):1-88. PubMed ID: 31852579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Significance of Sidedness in Patients with Metastatic Colorectal Cancer Treated with Triplet First-line Chemotherapy.
    Bazarbashi S; Omar AT; Raddaoui L; Badran A; Alzahrani A; Aljubran A; Elhassan T
    Asian Pac J Cancer Prev; 2019 Oct; 20(10):2891-2896. PubMed ID: 31653131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
    Iveson TJ; Kerr RS; Saunders MP; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Scudder C; Boyd KA; Briggs A; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan HS; Paul J
    Lancet Oncol; 2018 Apr; 19(4):562-578. PubMed ID: 29611518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Primary Tumor Sidedness for Unresectable Stage IV Colorectal Cancer: A Retrospective Study.
    Shida D; Tanabe T; Boku N; Takashima A; Yoshida T; Tsukamoto S; Kanemitsu Y
    Ann Surg Oncol; 2019 May; 26(5):1358-1365. PubMed ID: 30719633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
    Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
    Ann Oncol; 2017 Aug; 28(8):1862-1868. PubMed ID: 28449055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
    Cascinu S; Poli D; Zaniboni A; Lonardi S; Labianca R; Sobrero A; Rosati G; Di Bartolomeo M; Scartozzi M; Zagonel V; Pella N; Banzi M; Torri V
    Eur J Cancer; 2019 Apr; 111():1-7. PubMed ID: 30797014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
    JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
    Li S; Zhu L; Yao L; Xia L; Pan L
    BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
    Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
    J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
    Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
    JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does Primary Tumor Side Matter in Patients with Metastatic Colon Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?
    Kelly KJ; Alsayadnasser M; Vaida F; Veerapong J; Baumgartner JM; Patel S; Ahmad S; Barone R; Lowy AM
    Ann Surg Oncol; 2019 May; 26(5):1421-1427. PubMed ID: 30815802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of primary tumor location in Stage III colorectal cancer-right-sided colon versus left-sided colon versus rectum: a nationwide multicenter retrospective study.
    Shida D; Inoue M; Tanabe T; Moritani K; Tsukamoto S; Yamauchi S; Sugihara K; Kanemitsu Y
    J Gastroenterol; 2020 Oct; 55(10):958-968. PubMed ID: 32651860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of primary tumor sidedness and sex on unresectable post-recurrence survival in resected pathological stage II-III colorectal cancers: a nationwide multicenter retrospective study.
    Abe S; Kawai K; Nozawa H; Sasaki K; Murono K; Emoto S; Ozawa T; Yokoyama Y; Nagai Y; Anzai H; Sonoda H; Yamauchi S; Sugihara K; Ishihara S
    BMC Cancer; 2022 May; 22(1):486. PubMed ID: 35501727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of primary tumor localization on survival and treatment outcomes in patients with metastatic colorectal cancer-a multicenter study.
    Sahin S; Karatas F
    J BUON; 2019; 24(2):479-487. PubMed ID: 31127994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
    Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
    Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.